Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 19% Improvement Relative Risk Ventilation -67% Mortality (b) 2% levels Acute hypoxemic respirat.. 37% levels c19early.org/d Mazziotti et al. Vitamin D for COVID-19 LATE Is late treatment with vitamin D beneficial for COVID-19? Retrospective 348 patients in Italy Lower mortality (p=0.49) and higher ventilation (p=0.08), not stat. sig. Mazziotti et al., J Endocrinol. Invest., doi:10.1007/s40618-021-01535-2 Favors vitamin D Favors control
Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19
Mazziotti et al., J Endocrinol. Invest., doi:10.1007/s40618-021-01535-2
Mazziotti et al., Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients.., J Endocrinol. Invest., doi:10.1007/s40618-021-01535-2
Mar 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 348 hospitalized patients in Italy showing vitamin D deficiency associated with acute hypoxemic respiratory failure. Vitamin D supplementation during hospitalization was not significantly associated with mortality or ventilation.
risk of death, 19.0% lower, OR 0.81, p = 0.49, treatment 116, control 232, supplementation, RR approximated with OR.
risk of mechanical ventilation, 67.0% higher, OR 1.67, p = 0.08, treatment 116, control 232, supplementation, RR approximated with OR.
risk of death, 2.4% lower, RR 0.98, p = 0.91, high D levels 187, low D levels 161, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, control prevalance approximated with overall prevalence, outcome based on serum levels.
risk of acute hypoxemic respiratory failure, 37.0% lower, RR 0.63, p = 0.006, high D levels 72 of 187 (38.5%), low D levels 97 of 161 (60.2%), NNT 4.6, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >12ng/mL, outcome based on serum levels.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mazziotti et al., 5 Mar 2021, retrospective, Italy, peer-reviewed, 11 authors, dosage varies.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: Journal of Endocrinological Investigation (2021) 44:2285–2293 https://doi.org/10.1007/s40618-021-01535-2 ORIGINAL ARTICLE Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID‑19 G. Mazziotti1,2 · E. Lavezzi2 · A. Brunetti1,2 · M. Mirani2 · G. Favacchio2 · A. Pizzocaro2 · M. T. Sandri3 · A. Di Pasquale4 · A. Voza5 · M. Ciccarelli4 · A. G. Lania1,2 · Humanitas COVID19 Task Force Received: 4 January 2021 / Accepted: 11 February 2021 / Published online: 5 March 2021 © Italian Society of Endocrinology (SIE) 2021 Abstract Purpose Hypovitaminosis D has emerged as potential risk factor for severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection in the general population with variable effects on the outcome of the coronavirus disease-19 (COVID-19). The aim of this retrospective single-center study was to investigate the impact of hypovitaminosis D and secondary hyperparathyroidism on respiratory outcomes of COVID-19. Methods Three-hundred-forty-eight consecutive patients hospitalized for COVID-19 at the IRCCS Humanitas Research Hospital, Rozzano, Milan (Italy) were evaluated for arterial partial pressure oxygen (PaO2)/fraction of inspired oxygen (FiO2) ratio, serum 25hydroxy-vitamin D [25(OH)D], parathyroid hormone (PTH) and inflammatory parameters at study entry and need of ventilation during the hospital stay. Results In the entire population, vitamin D deficiency (i.e., 25(OH)D values < 12 ng/mL) was significantly associated with acute hypoxemic respiratory failure at the study entry [adjusted odds ratio (OR) 2.48, 95% confidence interval 1.29–4.74; P = 0.006], independently of age and sex of subjects, serum calcium and inflammatory parameters. In patients evaluated for serum PTH (97 cases), secondary hyperparathyroidism combined with vitamin D deficiency was significantly associated with acute hypoxemic respiratory failure at study entry (P = 0.001) and need of ventilation during the hospital stay (P = 0.031). Conclusion This study provides evidence that vitamin D deficiency, when associated with secondary hyperparathyroidism, may negatively impact the clinical outcome of SARS-CoV-2-related pneumonia. Keywords PTH · Vitamin D · Hyperparathyroidism · Vitamin D deficiency · COVID-19 · SARS-CoV-2 infection · Pneumonia
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit